Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19286312 | 1.00 | KDM4E (0.33) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL15012994 | 1.00 | KDM4E (0.33) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL19917246 | 0.88 | KDM4E (0.32) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL13948992 | 0.88 | KDM4E (0.32) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL16317653 | 0.88 | KDM4E (0.32) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL20886099 | 0.87 | — | — | |
| SCHEMBL14140850 | 0.86 | — | — | |
| SCHEMBL16449961 | 0.86 | — | — | |
| SCHEMBL14140905 | 0.85 | — | — | |
| SCHEMBL16449959 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744528-B2 | Metallorganocatalysis for asymmetric transformations | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150045556-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | DOLLE ROLAND E (US) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045556-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | OPRK1, OPRM1, OPRD1 | KDM4E 4138/4885MEN1 4735/4885ALDH1A1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.